| |
| | Joined: Jun 2013 Posts: 262 Gold Member (200+ posts) |  Gold Member (200+ posts)
Joined: Jun 2013 Posts: 262 | Hang in there, Matthew! I'm glad your team hooked you up with the dermatologist, it sounds like you're in great hands.
53
T3N2aM0 HPV+
5/26/13 discovered painless superball-sized lymph node in neck
6/26/13 DX SCC R palatine tonsil
7/16/13 TORS tonsillectomy & selective ND, mets to 2 nodes
9/3/13 Cisplatin and rads begin, tolerated 1.5 of 3 planned chemo doses
10/16/13 Treatment ends
Dec 13 Ulcer appears at surgery site
Jan 17 Biopsy -- no cancer!
Feb 17 CT/PET Scan lights up tonsil bed & nasal cavity, docs say probably inflammation, don't panic, rescan when ulcer subsides
| | | | | Joined: Dec 2013 Posts: 26 Contributing Member (25+ posts) | | OP Contributing Member (25+ posts)
Joined: Dec 2013 Posts: 26 | Thanks Mamacita, I'm chipping away one swing at a time! Just finished my second week and my rash is finally letting me think straight. My face has literally been on fire to the point where I had to put my face in front of the AC to get any relief. 5 days of that and I think finally the Keflex has started to kicked in. The topical steroids only seemed to make my face worse--Desonide and Lidex. Seems like everyone who talks about their rash from Cetuximab has only spoke of the cosmetic aspect but my rash has all been about the pain. Has anyone else had the burning pain on the face as well? What did you do? thanks for listneing
40 yr old male--very active, ns, rarely drink
T4aN0M0 HPV+
11/21/13--Lesion on back right of tongue, biopsy neg, CT neg
11/25/13--2nd biopsy DX SCC BOT
12/21/13--T4aN0M0 via PET and MRI scans
12/30/13--Begin Cetuximab/Rad Treatment
Treatment currently at Stanford Medical Center
2/14/14--Finished 36 rad treatments
2/18/14--Finished 8 cetuximab infusions-completion of treatment
4/26/2014--MRI showed marked tumor regression
5/27/2014--PET clear
8/18/2014--MRI clear
2/22/2015--MRI clear
| | |
| Forums23 Topics18,245 Posts197,129 Members13,316 | | Most Online1,788
Jan 23rd, 2025 | | |
|
| |
